Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹692.1b

Aurobindo Pharma Balance Sheet Health

Financial Health criteria checks 5/6

Aurobindo Pharma has a total shareholder equity of ₹308.8B and total debt of ₹84.3B, which brings its debt-to-equity ratio to 27.3%. Its total assets and total liabilities are ₹480.9B and ₹172.1B respectively. Aurobindo Pharma's EBIT is ₹50.1B making its interest coverage ratio 41.2. It has cash and short-term investments of ₹68.7B.

Key information

27.3%

Debt to equity ratio

₹84.27b

Debt

Interest coverage ratio41.2x
Cash₹68.68b
Equity₹308.85b
Total liabilities₹172.09b
Total assets₹480.94b

Recent financial health updates

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Recent updates

Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Jan 24
Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Financial Position Analysis

Short Term Liabilities: AUROPHARMA's short term assets (₹262.3B) exceed its short term liabilities (₹143.4B).

Long Term Liabilities: AUROPHARMA's short term assets (₹262.3B) exceed its long term liabilities (₹28.7B).

Debt to Equity History and Analysis

Debt Level: AUROPHARMA's net debt to equity ratio (5%) is considered satisfactory.

Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 40% to 27.3% over the past 5 years.

Debt Coverage: AUROPHARMA's debt is not well covered by operating cash flow (18.8%).

Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (41.2x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 15:23
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurobindo Pharma Limited is covered by 53 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Kamlesh KotakAsian Markets Securities Private Limited
Harith AhamedAvendus Spark